Omnicell (OMCL) Tops Q4 EPS by 24c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Omnicell Announces Fiscal Year and Fourth Quarter 2022 Results
February 28, 2023 4:01 PM EST2022 Total Bookings of $1.054 billion
Full Year 2022 GAAP Revenues of $1.296 and non-GAAP Revenues of $1.297 billion
Ended Year with Over 150 Long-Term, Sole-Source Agreements with the Top 300 U.S. Health Systems
Year End 2022 Backlog of $1.215 billion
Chief Financial Officer to Step Down effective July 1, 2023
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL) (Omnicell, we, our, us, management, or the Company), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results... More
